INNOVIVA, INC. Available-for-sale Securities, Gross Realized Gain (Loss)
INNOVIVA, INC. (INVA) reported Available-for-sale Securities, Gross Realized Gain (Loss) of $9.00 thousand for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-26.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet · last filed 2013-02-26
- INNOVIVA, INC. available-for-sale securities, gross realized gain (loss) for fiscal 2012 was $9.00K.
- INNOVIVA, INC. available-for-sale securities, gross realized gain (loss) for fiscal 2011 was -$2.00K, a 166.67% decline from fiscal 2010.
- INNOVIVA, INC. available-for-sale securities, gross realized gain (loss) for fiscal 2010 was $3.00K.
| Period end | Available-for-sale Securities, Gross Realized Gain (Loss) 12 month |
|---|---|
| 2012-12-31 | $9.00K 10-K · filed 2013-02-26 |
| 2011-12-31 | -$2.00K 10-K · filed 2013-02-26 |
| 2010-12-31 | $3.00K 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |